Lipid mediators derived from essential fatty acids, such as arachidonic acid, play important roles in physiologic and pathophysiologic processes. Prostaglandins, thromboxane, and leukotrienes are well-known eicosanoids that play critical roles in hemodynamics and inflammation. New families of mediators were recently uncovered that constitute a new genus stimulating resolution of acute inflammation, and are organ-protective. These include the resolvins (E-series and Dseries), protectins (neuroprotectin D1/protectin D1), and maresins biosynthesized from omega-3 essential fatty acids. Phagocytes play major roles in tissue homeostasis and have a high capacity to produce these mediators, which depend on their tissue and state of activation. It is important to select appropriate methods for identifying target mediators and pathway biomarkers. In this unit, we review state-of-the-art approaches to identify and profile eicosanoid and docosanoid pathways, including specialized pro-resolving mediators resolvins, protectins, and maresins, in relation to their biosynthesis and inactivation by neutrophils and macrophages. 
INTRODUCTION
Arachidonic acid is precursor to potent local-acting mediators, also known as autocoids, which play key roles in physiological processes and pathophysiologic events including reproductive physiology, hemodynamics, renal function, and inflammation (Samuelsson, 1983; Samuelsson et al., 1987) . Macrophages play key roles in both host defense and in homeostatic tissue functions and thus have a wide range of functional phenotypes (Russell and Gordon, 2009) . Macrophages are endowed with the capability to generate diverse arrays of lipid mediators, depending on their state of activation, tissue of origin, and functional roles within the tissue (Fig. 14.26.1A) . For example, it is well appreciated that isolated human macrophages, when challenged in vitro, can generate prostaglandins, leukotrienes, or lipoxins, depending on the stimulus and substrate availability (Calorini et al., 2000) . The profiles of lipid mediators produced by macrophages are still an important area for cutting-edge research as macrophages, e.g., involved in resolution and tissue homeostasis, have the ability to produce novel lipid mediators ). These small molecules are potent and can alter the function of surrounding tissues, as well as play autocrine roles.
In addition to the families of arachidonic acid-derived mediators including prostaglandins, thromboxanes, leukotrienes, and lipoxins (Samuelsson et al., 1987) , human and murine phagocytes, such as neutrophils and macrophages, produce novel eicosanoids and docosanoids including the new families resolvins (resolution phase interaction products carrying bioactivity), protectins, and maresins (Serhan et al., 2000 (Serhan et al., , 2002 . The term eicosanoid refers to the carbon-20 backbone and docosanoid refers to the carbon-22 backbone. Both arachidonic acid (AA) and eicosapentaenoic acid (EPA) are C:20 carbon structures (C20:4 and C20:5, respectively). EPA has five double bonds and AA has four; the bonds are not conjugated. Docosahexaenoic acid (DHA) is denoted C22:6, indicating that it has six unsaturated double bonds. These essential fatty acids, particularly EPA and DHA, are enriched in marine oils and are not synthesized to any great extent in mammalian tissues; thus, they are required in the diet (Simopoulos et al., 1999) . AA is tightly regulated in its release and is evolved in phospholipid receptor-mediated signal transduction processes (Samuelsson, 1983; Samuelsson et al., 1987) . These events with EPA-and DHA-derived mediators have only recently become evident (Kasuga et al., 2008) . The resolvins, protectins, and maresins are derived from EPA and DHA and play protective, anti-inflammatory, and pro-resolving roles in many inflammatory disease models . In this unit, we focus on current state-of-the-art approaches to monitor the production of prostaglandins, leukotrienes, and lipoxins from AA by human and murine phagocytes, as well as to monitor the docosanoids including the new genus of specialized pro-resolving mediators (SPM) produced by phagocytes, such as resolvins, protectins, and maresins. Since the profiling of these biosynthetic pathways in phagocytes can also yield biologically inactive metabolites and related but inactive isomers of the specific mediators (i.e., trans isomers of LTB 4 , LXA 4 , RvE1, RvD1), we focus this unit on the procedures required to identify the bioactive target mediator, as well as their related biosynthetic profile or pathway metabolome in phagocytes. Some of the cell isolation protocols and procedures have been reviewed elsewhere (Chiang and Serhan, 2006) . The focus of this unit is on current methods for state-of-the-art identification of the potent bioactive mediators derived from essential fatty acids (Fig. 14.26.1) . Table 14 .26.1 contains a list of abbreviations and trivial names and glossaries used throughout the unit.
Experimental Design for Eicosanoid and Docosanoid Biosynthesis
Whole blood in the peripheral venous circulation of healthy individuals typically has 1.8 to 7.7 × 10 9 neutrophils (54% total leukocytes)/liter and 130 to 400 × 10 9 platelets/liter. The ratio of neutrophils to platelets markedly increases at sites of vascular inflammation, as these cell types physically interact and total neutrophil numbers dramatically rise (Cotran et al., 1999) . In the presence of local agonists, such as thrombin and chemotactic peptides, and circulating agents, such as granulocyte/monocyte colony-stimulating factor (GM-CSF) and other cytokines, plateletneutrophil interactions lead to the elaboration of lipid mediators that modulate the inflammatory host response and mediate the repair of tissue injury. Dissecting the products, their biosynthesis, and the factors that regulate their formation requires an organized experimental approach (Serhan and Sheppard, 1990; Serhan et al., 2000) .
The capacity of individual cell types to generate eicosanoids and/or docosanoids can be evaluated, and, if cell-cell interactions are likely to occur during physiological or pathophysiological states, conditions can be simulated or modeled ex vivo to determine the presence of transcellular pathways for eicosanoid formation (Chiang and Serhan, 2006) . When investigating transcellular biosynthesis during cell-cell interactions (in vitro), it is critical to examine LM (eicosanoid and docosanoid) profiles during each of the following incubation conditions:
• Basal profile of individual cell type (i.e., without agonist);
• Individual cell type after activation by cell type-specific agonist;
• Stimulation of cells during co-incubation using individual cell type-specific agonist;
• Co-stimulation of both cell types during co-incubation using shared
• Receptor-independent stimuli, as well as receptor-mediated stimuli.
A range of agonists have been studied including phagocytic stimuli (e.g., opsonized zymosan, immune complexes, apoptotic neutrophils, and urate crystals) and soluble stimuli (e.g., chemotactic peptides, thrombin, calcium ionophores, complement components, and platelet-activating factor and cytokines; see Table 14 .26.2 and references therein). Notably, the biosynthetic profile for LT and LX formation during co-incubation of differing cell types is unique to the agonists used to activate the cells. The most physiologically relevant stimuli are those that mediate their effects via activation of cellular receptors (e.g., thrombin or GM-CSF), while stimuli that bypass membrane receptors (e.g., calcium ionophores) are potent cellular agonists yet often give a profile of eicosanoid products that is markedly different, both qualitatively and quantitatively, from those obtained with receptor-mediated stimuli. Hence, ionophores can be used to probe the capacity of isolated cells or tissues to produce eicosanoids and/or docosanoids.
To determine the eicosanoid profile of an individual cell type, it is often useful to expose isolated cells during co-incubation to cell type-specific agonists. For example, expose TOF: time-of-flight, which is used to determine the mass-to-charge ratio in a mass spectrometer a neutrophil (PMN)-platelet (PLT) incubation to thrombin to determine the enzymatic contribution of the platelet. Incremental information can next be derived from co-incubations of cells in the presence of a cell type-specific agonist for PMN, such as the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP). Lastly, co-incubation of the two cell types with both relevant agonists often yields both increased amounts of the cell typespecific products and generation of novel products beyond the enzymatic capacity of either cell type in isolation (Chiang and Serhan, 2006) . In addition, each cell type can be labeled independently with a radioactive isotope substrate to determine (1) if polyunsaturated fatty acid or a biosynthetic intermediate is transferred between cells and (2) which enzymes are operative in each cell type in the generation of bioactive products (Marcus et al., 1982) .
Lipidomics for Monitoring Eicosanoids and Docosanoids Generated by Phagocytes
Routine lipidomic analyses for eicosanoids and docosanoids include using ELISA-, LC-UV-, GC-MS-and LC-UV-MS-MS-based IL-4 (Conrad et al., 1992) ; IL-13 (Nassar et al., 1994) 5-LO Zymosan (Birmelin and Decker, 1984) ; IgE (Patterson and Harris, 1981) ; Monosodium urate crystals (Reibman et al., 1986) LPS (Aderem and Cohn, 1988) ; TNF-α (Palmantier et al., 1994) ; GM-CSF (Palmantier et al., 1994) COX-2 Zymosan (Pouliot et al., 1998a) ; Monosodium urate crystals (Serhan et al., 1984b; Pouliot et al., 1998b) IL-1-β (Raz et al., 1988; Maier et al., 1990) ; LPS (Fu et al., 1990; Hla and Neilson, 1992) ; TNF-α (Pouliot et al., 1998a) ; fMLP (Pouliot et al., 1998a) ; TGF-β (Gilbert et al., 1994) ; GM-CSF (Herrmann et al., 1990) a Pharmacological inhibitors have been developed for each of these enzymes.
approaches as outlined in Figure 14 .26.1 (Lu et al., 2005 Serhan et al., 2007 Serhan et al., , 2008 . In order to fulfill the specific requirements of individual experiments, proper methods will be chosen according to the nature of the investigation as described below. The most reliable and sensitive lipidomic approach currently available is the use of LC-UV-MS-MS (liquid chromatography-ultraviolet spectrometrytandem mass spectrometry instrumentation) (Kiss et al., 1998; Yu et al., 1998; Deems et al., 2007; Ivanova et al., 2007) . LC-UV-MS-MS can provide more spectral characterization than LC-MS-MS. With the aid of LC-UV-MS-MS and other technologies in this laboratory, we identified the resolvins, protectins, and more recently, maresins, using physical properties including characteristic UV spectra and LC retention times, as well as mass spectra (Serhan et al., 2000 (Serhan et al., , 2002 Hong et al., 2003) . The correlation of MS-MS fragments to structures of some LM and their isomers have been studied (Murphy et al., 2001; Hong et al., 2007; Lu et al., 2007) . These results indicate that MS-MS spectra are readily elucidated for the double bonds and functional groups of fatty acids. ELISA (enzyme-linked immunosorbent assay) has been introduced as an approach for lipid mediator quantitation, and it is designed for quantification of specific LM with relatively high selectivity and sensitivity (Chiang et al., 2004) . It allows investigators to assess one specific analyte in a large number of samples in a timely fashion (Chiang et al., 2004) . The availabilities and cross-reactivities between analytes are the main concern for choosing this method. LC-UV-based lipidomics requires neither expensive instrument nor a specific reagent, and is a widely used technique for eicosanoid analysis (Serhan, 1990) . Liquid chromatography coupled with UV spectrometry (LC-UV) relies on retention time and online UV spectrum to identify and quantify LM (Fig. 14.26 .1). The limitation of this method is that the peaks might not be well resolved (co-elution) and/or the analytes lack useable chromophores. LC-UV is used mostly for convenient screening and/or compound isolation (i.e., isolation of intermediates, purification of substrates, etc.; see below). Gas chromatography coupled with mass spectrometry (GC-MS) has long been the method of choice for routine lipidomics of fatty acids and eicosanoids (Ackman, 1984; Serhan et al., 1984a,b) . Multiple analytes can be detected in one sample after derivatization (Serhan, 1990) ; however, GC/MS is not ideally suitable for all intact lipids or lipid mediators because pretreatment, as well as derivatization, are required for some classes of compounds (Murphy et al., 2005; Ivanova et al., 2007) . It is often used together with LC-UV-MS-MS to confirm structure elucidation, quantitation, as well as identification (Serhan et al., 1984a; Serhan et al., 2000; Kasuga et al., 2008 Most used methods for lipidomics (see Table 14 .26.4 for instrument selection; Powell, 1999; Deems et al., 2007; Ivanova et al., 2007; Schwab et al., 2007; Adler et al., 2009) GC-MS 100 ng Detection of multiple analytes in one acquisition without specialized (targeted) methods.
Derivatization is required. Not suitable for all LM.
Fatty acids. Together with LC-UV-MS-MS for identification, profiling, and structure elucidation (Serhan et al., 1984a; Christie, 2003) LC-UV 1 ng Online UV and retention time.
Coelution of analytes with similar retention times. Analyte UV chromophore is required.
Convenient assessments and purifications of compounds with UV chromophores (Wei et al., 2006; Schneider et al., 2007; Serhan et al., 2009) ELISA 1 pg to 5 pg High sensitivity and selectivity. Time efficient assessment of large numbers of samples.
Availability for only certain LM. Cross-reactivity between analytes.
One specific LM (e.g., PGE 2 , PGD 2 , LTB 4 , LXA 4 (Chiang et al., 2004) High sensitivity, high mass accuracy for LM identification, and structure elucidation analysis, the results will be validated with LC-UV-MS-MS (Chiang et al., 2004) . ELISA kits
are not yet available for all eicosanoids and docosanoids.
Sample Preparation and Extraction for LC-UV-, LC-UV-MS-MS-, and GC-MS-Based Lipidomics
Before samples are subject to LC-UV-, LC-UV-MS-MS-, and GC/MS-based analyses, extraction can be used, and, in most cases, is required, to increase both the specificity and sensitivity (Powell, 1999) . Solid-phase extraction is one of the most used extraction techniques (Powell, 1999; Lu et al., 2006; Deems et al., 2007) . The following solidphase extraction procedures are optimized for maximum lipid mediator recovery yield , which should ideally be >90% to 95%. Following the addition of two volumes of cold methanol to incubations or tissue samples, they are stored at −20
• C for 30 min to 1 hr. Samples are extracted with deuterium-containing synthetic or authentic compounds as internal standard (IS) to assess recovery yields and to determine extraction efficiencies (Merched et al., 2008) . Ideally, the corresponding deuterated compounds are chosen as IS for an analyte, e.g., synthetic d-2 RvD1 is used to quantitate RvD1 in biological samples. If corresponding deuterated compound is not commercially available, deuterium-labeled docosanoids or eicosanoids with similar polarity to the analyte of interest can be used for estimating the recovery, e.g., d-4 LTB 4 for quantitating dioxygenated products. Our commonly used deuteriumlabeled internal standards (IS) are listed in Figure 14 .26.2. Samples are centrifuged at 10 min at 800 × g, 4
• C, and the supernatant is collected. Pellets are suspended in 1 volume of cold ethanol and the centrifuge repeated. The supernatants are combined and organic solvent evaporated with nitrogen gas or a concentrator (Savant SpeedVac). Samples are then suspended in 10% methanol (e.g., 9 ml H 2 O and 1 ml methanol), followed by acidification to pH 3.5.
Before the extraction, C-18 solid-phase extraction cartridges should be rinsed with 20 ml methanol and then 20 ml ddH 2 O. Acidified samples will be loaded into the cartridges. The cartridges are eluted with 10 ml of hexane, 8 ml of methyl formate, and then 10 ml MeOH. Fractions are collected, e.g., most of the fatty acids will be enriched in hexane fractions, eicosanoids and docosanoids are enriched in methyl formate fractions, and peptido-conjugates (i.e., LTD 4 ) enriched in methanol fractions (Powell, 1999) . Remove the solvent either with nitrogen or SpeedVac and suspend the residues in mobile phase immediately prior to the next step of assessment. To minimize potential auto-oxidation and isomerization of analytes, incubation/sample preparations should be subjected to LM lipidomic procedures immediately and not stored for long periods.
HPLC-Based Lipidomics
LC-UV relies on retention time and online UV spectrum to identify and quantify LM. We will use LC-UV for rapid and costeffective lipidomic screenings or compound isolations. For example, leukotrienes (LTs) in methanol have a conjugated triene with λmax ∼270 nm for LTB 4 and diHETEs and λmax ∼280 nm for cysteinyl LTs, while both LX and 15-epimer-LX (aspirin-triggered lipoxins) have a conjugated tetraene with λmax ∼300 nm (Fig. 14.26 .5). Although PGB 2 carries a UV chromophore with λmax ∼280 nm, most prostanoids absorb UV at λmax <210 nm, all of which fall in the cut-off wavelength range of LC eluents. Thus, most prostanoids, as well as the LM, without proper chromophores are not suitable for LC-UVbased lipidomics (Masoodi and Nicolaou, 2006) . In this laboratory, HPLC is often used for initial lipidomic screening and compound isolation/purification (Fig. 14.26.3) .
Polyunsaturated fatty acids (PUFAs) are subject to auto-oxidation and lead to the generation of a series of oxygenated products (Yin et al., 2007) . Thus, it is necessary to routinely monitor and isolate/purify PUFAs immediately before use. Figure 14 .26.3A shows isolation/purification of commercial DHA with RP-HPLC. Insets show online UV spectra of DHA and its auto-oxidation products-monohydroxydocosahexaenoic acids (HDHA)/monohydroperoxydocosahexaenoic acids (HpDHA). GC/MS analysis of HPLC-isolated DHA is shown in Figure 14 .26.3B. Only one dominant peak confirms its high purity. The isolation was conducted with 1100 Agilent HPLC equipped with a UV detector using a C18 column (4.6 mm × 150 mm × 5 μm; Agilent Eclipse XDB) and a mobile phase consisting of 80% to 100% MeOH/H 2 O with 0.01% AcOH over a 30-min ramp at 1 ml/min ). This approach can also be conducted for isolating other PUFAs and reagents.
LC-UV-MS-MS-Based Lipidomics
LC-UV-MS-MS-based mediator lipidomics includes identification/matching, validation, profiling, structure elucidation, as well as defining novel lipid mediators (LM) stereochemistry and its biosynthesis, as outlined in Figure 14 Table 14 .26.5. Unmatched analytes may be subject to bioactivity assessment, as well as QTOF (Qstar) and GC/MS-aided structure elucidation (Lu et al., 2005) . For potent bioactive compound(s), isotope trapping and chiral lipidomics of biosynthesis marker(s) are carried out to determine the biosynthesis pathway(s) ), which will also help to define the stereochemistry of the novel compound. Then, total organic synthesis of a series of potential candidates will be undertaken elsewhere for matching. Eicosanoids and docosanoids are potent autocoids with high stereospecificity; meanwhile, it is impossible to obtain stereochemistry information directly from LC-UV-MS-MS-based lipidomics. It is important to match the physical properties of synthetic candidates, which are then matched with endogenous ones to determine their complete stereochemistry, in addition to matching with bioactivities (Arita et al., 2005; Serhan et al., 2006; Sun et al., 2007; Spite et al., 2009 The matching/identification will usually be undertaken with at least two different instruments/solvent systems. Matching/identification criteria include LC retention time, maximum absorbance wavelength (λmax) and band shape of UV, and ≥ 6 diagnostic ions of tandem MS-MS spectrum, as shown Figure 14 .26.5 .
The instrumentation used for LC-UV-MS-MS-based lipidomics includes LCQ, Qtrap 3200, and Qstar XL. The instrument selection will be based on the aspects of each instrument as shown in Table 14 .26.4. Fast acquisition in MRM mode, high sensitivity, and high linear dynamic range of Qtrap 3200 make it optimum for LM profiling (Deems et al., 2007) . LCQ can be used as an alternative and a backup for this purpose if the Qtrap 3200 is down or requires maintenance. Its capability of multistage mass spectral analysis makes LCQ ideal for structure elucidation. Qstar is predominantly used for LM identification and structure elucidation when high sensitivity and high mass accuracy are required.
Routine Lipidomics for Eicosanoids and Docosanoids
Typical lipidomic/metabolomic analysis for eicosanoids and docosanoids can use an Agilent 1100 series HPLC coupled with an ABI 3200 Qtrap mass spectrometer equipped with an Agilent Eclipse Plus C18 column (4.6 mm × 50 mm × 1.8 μm). For ABI Qtrap 3200 mass spectrometer-based lipidomics, instrument control and data acquisition are performed using Analyst 1.4.2 software. The instrument is run in negative ionization mode. For targeted mediator lipidomics, acquisition mode will be Enhanced Product Ion (EPI). The mobile phase consists of ethanol/water/acetic acid (60/40/0.01; v/v/v) and is ramped to 80/20/0.01 (v/v/v) over 7.5 min and to 95/5/0.01 (v/v/v) over the next 4.5 min at a flow rate of 400 μl/min. The flow rate will be decreased to 200 μl/min for 3 min, then will be returned to 400 μl/min and the mobile phase will be ramped up over the next 6 min to ethanol/water/acetic acid 100/0/0. IDA criteria: intense peaks from 1 to 1, or 1 to 2; intense peaks exceeds 200 counts; mass tolerance, 250 mamu. Conditions for MS-MS are: electric spray voltage, 4.2 kV; source temperature, 500
• C; Gas1, 50 units, Gas2, 50 units; Curtain Gas, 20 units; Collision Gas, medium. For EPI mode, Declustering Potential (DP), −35 V; Entrance Potential (EP), −5 V; Collision Cell Entrance Potential (CEP), −12.7 V. For MRM mode, each parameter is optimized individually. For Finnigan LCQ-based lipidomics, the general conditions will be as follows. The mobile phase will flow at 0.2 ml/min as C (methanol:water:acetic acid 65:35:0.01) from 0 to 8 min, will be ramped to methanol from 8.01 to 30 min, then will flow as methanol for 10 min, and then will run as C again for 10 min. The photodiode-array UV detector will scan from 200 to 360 nm. Conditions for MS-MS will be: electric spray voltage, 4.3 kV; heating capillary, 230
• C and -39 V; tube lens offset, 60 V; sheath N 2 gas, 80 units (near 1.2 liter/min); auxiliary N 2 gas, 3 units (0.045 liter/min).
Next, after positive identification/ matching, quantitation is usually carried out. Fast acquisition, high sensitivity, and high dynamic range make MRM ideal for profiling/quantitating multiple analytes (Deems et al., 2007) . Currently, we routinely profile and quantitate up to 52 LM within a single experiment and LC-MS profiling. The representative MRM transitions are shown in Table 14 .26.5. Individual methods are tailored to fit the specific requirements of individual investigations. of chromatogram, MS-MS spectrum, and online UV of RvE1 and RvD1 . Eicosanoid and docosanoid biosynthesis are temporally dissociated in inflammation/resolution. Their productions switch from pro-inflammatory mediators to antiinflammatory pro-resolving signals, such as lipoxins, resolvins, protectins, as well as maresins during resolution phase . Along with the regulation of these signals, monocytes/macrophages are recruited to the inflamed site for nonphlogistic clearance of apoptotic PMN, pathogens and cell debris, et al. (Lawrence and Gilroy, 2007; Serhan et al., 2008) . To elucidate temporal eicosanoid biosynthesis profiles in macrophage phagocytosis of apoptotic PMN, we applied ELISA-based lipidomic approach to in vitro incubation of elicited macrophages with apoptotic PMNs, and demonstrated the generation of endogenous anti-inflammatory pro-resolving LXA 4 was increased, and peaked at 15 min, but not pro-inflammatory Figure 14 .26.5 (Schwab et al., 2007) . Tandem mass spectrum of identified biogenic LXA 4 is shown in Figure 14 .26.7B. In the presence of aspirin, macrophage phagocytosis of apoptotic PMN also generates anti-inflammatory pro-resolving RvE1. Furthermore, RvE1 level increases when EPA is supplied (Fig. 14. 26.8) (Schwab et al., 2007) . Tandem mass spectra of authentic synthetic RvE1 and identified biogenic RvE1 from murine macrophages are shown. Signature ions, m/z 291, 195, 153, 129 , and 109 confirm the positive identification of biogenic RvE1 (Schwab et al., 2007) . These results are consistent with the nonphlogistic nature of the macrophage phagocytosis of apoptotic PMN with implication of amplification of resolution signals in resolution phase. A wide range of physiological and pathophysiological events involve cell-cell interactions, during which transcellular biosynthesis plays important roles in eicosanoid and docosanoid generations (Clària and Serhan, 1995; Serhan et al., 2000; Chiang et al., 2004; Morris et al., 2009) . Transcellular biosynthesis of aspirin-triggered lipoxins (ATL) was established during endothelial-PMN interaction in vitro (Clària and Serhan, 1995) , and demonstrated in vivo in humans (Chiang et al., 2004 ; 
Morris et al., 2009
). RvE1 was originally isolated and identified in murine resolving exudates, and the in vivo events were recapitulated with human cells in vitro (Serhan et al., 2000) . Aspirin is well documented to block thromboxane formation via permanently acetylating and inhibiting platelet cyclooxygenase-1 (COX-1), which could account for aspirin's anti-thrombotic properties. In addition, aspirin acetylates vascular cyclooxygenase-2 (COX-2) and switches its activity from generating PG and TX to producing 15R-H(p)ETE. 15R-H(p)ETE is then transformed by leukocyte 5-lipoxygenase to aspirin-triggered lipoxins (ATL). Along these lines, aspirin-acetylated COX-2 also converts EPA to 18R-HEPE, which is released and then rapidly converted by 5-lipoxygenase in leukocytes to generate RvE1. Therefore, aspirin can jumpstart resolution by initiating generation of aspirin-triggered lipoxins and AT-resolvins, which enhance resolution rather than have a negative impact on this essential process (Schwab et al., 2007) . The overall regulation of eicosanoid and docosanoid generation by aspirin is shown in Figure 14 .26.9.
LC-MS-MS-Based Pathway Metabolomics of Eicosanoids and Docosanoids
Inflammation and resolution are actively regulated processes involving timed generation and inactivation of endogenous signals, where phagocytes, particularly macrophages, are major determinants . E-series resolvins are potent antiinflammatory pro-resolving lipid mediators generated in the resolution phase . Like other eicosanoids and docosanoids, they are local-acting autocoids in that they are generated locally, exert their potent biofunctions, and then are rapidly inactivated (Serhan et al., 2000; Tjonahen et al., 2006; Hong et al., 2008) . Figure  14 .26.10 shows E-series resolvin biosynthesis and inactivation metabolome. Profiling of RvE1, RvE2, and their biomarker, 18-HEPE, is demonstrated with MRM chromatograms with transition m/z 317>259 for 18-HEPE, m/z 333>115 for RvE2, and m/z 349>195 for RvE1. Instrument set up and parameters for LC-UV-MS-MS-based lipidomics are described in Routine Lipidomics for Eicosanoids and Docosanoids (above). Major RvE1 metabolism pathways have also been decoded and are shown in Figure 14 .26.12. Several RvE1 metabolites, namely, 10, 11-dihydro-RvE1, 18-oxo-RvE1, 19-hydroxyRvE1, 20-hydroxy-RvE1, and 20-carboxyRvE1, have been detected in the incubations of RvE1 with mouse lung, liver, kidney, spleen, human whole blood, or isolated PMN (Hong et al., 2008) . RvE1 can be converted enzymatically first to an intermediate 12-oxo-RvE1, then rapidly reduced to 10,11-dihydro-12-oxo-RvE1 that can then be further converted to 10,11-dihydro-RvE1. Meanwhile, 20-carboxy-RvE1 is generated via further metabolic oxidation of 20-hydroxyRvE1. Tandem mass spectra of representative EPA metabolome biosynthesis and inactivation products, 18-HEPE, RvE2, RvE1 and its inactivated metabolite 20-COOH-RvE1, are shown in Figure 14 .26.11.
During resolution of inflammation, DHA can be utilized by cells, including phagocytes, to enzymatically generate a series of antiinflammatory pro-resolving docosanoids, including PD1 and RvD1 (for examples, see Serhan et al., 2002; Hong et al., 2003; Serhan et al., 2006; Sun et al., 2007) . RvD1 can be further metabolized by 15-prostaglandin dehydrogenase/eicosanoid oxidoreductase to form 17-oxo-RvD1 and 8-oxo-RvD1 (Sun et al., 2007) . 
LC-UV-MS-MS-Based Reversed-Phase Chiral Analysis
Lipids, and in particular polyunsaturated fatty acids, are subject to auto-oxidation, which leads to the formation of racemic mixtures of many compounds, such as isoprostanes (Yin et al., 2007) . In contrast, enzymatically produced mediators, especially through the lipoxygenase and cyclooxygenase routes, generate oxygenated products and intermediates that tend to possess predominant chiralities (Williams et al., 2005) . Thus, chiral separations and isomer ratios can be used to distinguish the nonenzymatic and enzymatic pathways of oxygenated lipid-derived products. LC-UV-MS-MS-based reverse phase chiral and lipid analysis enables direct assessment without derivatization; they have been utilized in recent years (Schneider et al., 2007; Serhan et al., 2009 ). LC-UV-MS-MS-based reversedphase chiral analysis is carried out using ABI 3200 Qtrap mass spectrometer coupled with an Agilent 1100 series HPLC with a ChiralPak AD-RH reversed-phase chiral column (Chiral Technology). The LC mobile phase gradient is set up at acetonitrile:water:acetic acid=70:30:0.05 (v/v/v) 0.2 ml/min. The mass spectrometer set up, the identification/matching, and the quantification are essentially as indicated above. Figure 14 .26.14 shows MRM chromatograms of chiral separation of racemic HDHA mixture (4-HDHA: m/z 343>101 in blue color, 7-HDHA: m/z 343>141 for 7-HDHA in orange, and 14-HDHA: m/z 343>205 in green). Chiralities were determined by matching with optically pure compounds usually defined by total organic synthesis using criteria as shown in Figure 14 .26.5.
Recently, a novel family of antiinflammatory and pro-resolving docosanoids -maresins (macrophage mediators in resolving inflammation)-has emerged, which was first uncovered as autocoids generated by murine peritoneal macrophages ). Its biosynthesis has been shown via 12-LOX in human macrophages and 12/15-LOX in murine tissues, which initiate the maresin biosynthetic pathway to produce maresin 1 (MaR1; Serhan et al., 2009 ). LC-UV-MS-MS-based chiral analysis of incubations of porcine leukocyte type 12-LOX with DHA demonstrated the 14-hydroxydocosahexaenoic acid (14-HDHA) as a major product. Incubations reduced with NaBH 4 before analysis demonstrated that >98% S-configuration carbon 14 alcohol was generated by the enzyme, as shown in Figure 14 .26.15A ). Chirality of 14-HDHA was determined by matching with authentic optical pure compounds using criteria shown in Figure 14 .26.5. Figure 14 .26.15B shows the mass spectrum of identified biogenic 14S-HDHA from the incubation. Hence, chiral LC-MS-MS can be very powerful in establishing biosynthetic pathways and stereochemistry of specific mediators. This is important because most bioactive eicosanoids and docosanoids are active in a chiral and stereospecific fashion. Hence, some oxidation products are completely devoid of actions and biological functions.
Lipidomic Databases and Searching Algorithms
Databases with appropriate searching algorithms are crucial for the timely identification of these LM via LC-UV-MS-MS analytical runs (Lu et al., 2005) . Lipid mediators are identified on the basis of chromatographic features, such as retention time, UV and MS-MS spectrum. We modified and refined the available software package Mass Frontier to perform database algorithm searches based on tandem mass spectrum, retention time, and UV spectrum (Ivanova et al., 2007) . The new program can perform algorithmic search for real databases, as well as theoretical databases with UV and MS-MS spectra of a large number of theoretical compounds. Thus far, the database contains over 30 bioactive LM and over 1000 theoretical fatty acid-derived compounds and fragments for putative endogenous local mediators.
We are currently building a new database for the newly purchased Qtrap 3200 (work in progress). Lipid mediators are identified on the basis of chromatographic features, such as retention time, UV and MS-MS spectra. An example of Qtrap database searching is shown in Figure 14 .26.16.
GC/MS-based lipidomics
GC-MS provides unique information and opportunity for fatty acids and lipid mediator research (Serhan et al., 1984a; Christie, 2003) . After derivatization, multiple analytes can be detected in one sample without specialized methods (Serhan et al., 1984a; Christie, 2003) . The overview of GC/MS procedure is shown in Figure 14 .26.17A. After derivatization of lipid mediators sample is subject to GC/MS analysis. The results are then assessed by data mining through the NIST database. The GC-MS identification is conducted by matching the mass spectra and C-values of unknowns to LM standards. C-values are used instead of retention time to enable comparison of acquisition data obtained from different instruments or different methods ). Analyte C-value is determined using calibration curve of retention time vs. carbon numbers of a series of saturated fatty acid methyl esters (Lipid standards C14:0-C24:0; Sigma-Aldrich, cat. no. 18917), as shown in Figure 14 .26.17 panels B and C. After the compounds of interest are identified, they will be quantified on the basis of their chromatographic peak areas and linear calibration curves of chromatographic peak areas of authentic and synthetic eicosanoids and docosanoids. Worthy of note, the NIST GC/MS database is commercially available, and can be integrated to GC/MS analysis tools to facilitate data mining (Agilent). GC/MS is often used together with LC-UV-MS-MS to confirm identification, quantitation, and quality control of eicosanoids and docosanoids (Serhan et al., 2002 Kasuga et al., 2008) . Figure 14 .26.3B shows the total ion chromatogram (TIC) of derivatized isolated DHA. One dominant peak confirms the integrity of DHA.
SUMMARY
In summation, in this unit we provide an overview of the current state-ofthe-art approaches to identify and quantitate bioactive eicosanoids and docosanoids including prostaglandins, leukotrienes, and lipoxins produced from arachidonic acid, as well as resolvins, protectins, and maresins biosynthesized from omega-3 fatty acids (e.g., EPA and DHA). Emphasis is placed on the metabolic profiles of these products produced by phagocytes, in particular peripheral blood neutrophils, inflammatory exudates, and macrophages. State-of-the-art techniques reviewed here take advantage of LC-tandem mass spectrometry-based lipidomics for metabolic profiling of the lipid mediators produced by isolated phagocytes. The state of activation of neutrophils and whether they are of peripheral origin or from a site of inflammation dictate the profile of lipid mediators generated. Likewise, macrophages, depending on their functional role and state of activation, have an unusually high capacity to generate a wide range of potent bioactive mediators derived from essential fatty acids. Here, we provide examples of the metabolic profiles obtained from these cells with an emphasis on targeting potent bioactive mediators. In addition, criteria for full identification and matching to synthetic material, as well as quantitation using internal standards are reviewed. Metabolomic profiling with phagocytes gives a wealth of information. In addition to bioactive mediators, inactive isomers are products that can be used as biomarkers of pathway activation (i.e., biomarkers include 12-HETE, 14-HDHA and all-trans-LTB 4 within these pathways). Since many of these potent mediators are autocoids, they are transiently produced in vitro, as well as in vivo and are further metabolized to biologically inactive products. Profiling of these metabolic inactivation products and their relationship to the target bioactive compound (i.e., LTB 4 , RvE1, RvD1, etc.) are also presented, and examples given as illustrations. We trust that with this review the reader will find useful information for identification and profiling of individual bioactive lipid mediators and urge the reader to access the cited literature to provide further detail on the biosynthesis, actions, and functional roles of the pathways, bioactive mediators, and related compounds produced by phagocytes reviewed here. The approach and methods presented for phagocytes and inflammatory exudates are of wide utility and can be used in other organs and tissues to identify specific eicosanoids and docosanoids, profiles that can be location (tissue) and/or disease sitespecific.
